Randomized phase II study of TX followed by XELOX versus the reverse sequence for chemo-naive patients with metastatic gastric cancer

Randomized phase II study of TX followed by XELOX versus the reverse sequence for chemo-naive patients with metastatic gastric cancer

This research found that the clinical outcomes (PFS, ORR, OS) of the non-platinum-based doublet regimen (docetaxel capecitabine combination) were similar to those of the platinum-based (oxaliplatin capecitabine combination) when used as first line therapy for MGC patients.BackgroundDocetaxel, platin...

Full description

Bibliographic Details
Main Authors: Xiao-Yin Zhao, Xin Liu, Wen-Hua Li, Li-Xin Qiu, Ming-Zhu Huang, Chen-Chen Wang, Zhi-Yu Chen, Wen Zhang, Wan-Jing Feng, Wei-Jian Guo, Xiaodong Zhu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Oncology
Subjects:
Stomach neoplasm (gastric cancer)
chemotherapy
docetaxel (DOC)
capecitabine
oxaliplatin (L-OHP)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.911160/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.911160/full

Similar Items